Since the 2018 Farm Bill was signed this past December by the President, the FDA, lead by Scott Gottlieb, has been judiciously looking into the subject in order to figure out how to regulate Hemp, CBD and products infused with it.
Since then, we’ve been eagerly waiting for the first public hearing to be announced… And it finally has!
The first ever FDA public hearing aimed towards the regulation of CBD has been scheduled for Friday, May 31, and the FDA has asked all of us to participate and comment on three specific subjects regarding CBD:
- Health and Safety Risks
- Manufacturing and Quality
- Marketing, Labeling and Sales
How do I participate?
Up until May 10th, you can submit a request to make an oral presentation at the hearing.
The Agency will also be receiving written comments on the subject until July 2 of this year, through:
- The Federal Regulations online comment form, or
- The FDA’s docket for public comment on this hearing, which is No. FDA-2019-N-1482.
Dockets Management Staff (HFA-305)
Food and Drug Administration
5630 Fishers Lane, Rm. 1061
Rockville, MD 20852
Information about the Public Hearing
Friday, May 31
8 a.m. to 6 p.m.
FDA White Oak Campus,10903 New Hampshire Avenue, Building 31, Conference Center, the Great Room (Rm. 1503), Silver Spring, MD 20993.
For non-FDA employees, the entrance is through Building 1.
This is a huge step forward for the United States, since it will lessen stigma related to cannabis and provide clear guidelines for quality and production.
Hopefully, a lot of us participate! The more people share their knowledge, input and experience, the better chances there are for the FDA to regulate CBD in a way that serves the community and contributes to medical development.
See you at the hearing!